Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, states today that it will be announcing its half year results for the six months ended 30 November 2020 on Monday, 15 February 2021.
Adam Hill, Chief Executive Officer, together with Matthew Hall, Chief Financial Officer, will host a presentation and conference call for analysts at 11:30am GMT on the day of the results.
For conference call details please contact Alexander Davis of FTI Consulting at [email protected] or 020 3727 1000.
The management team will also host on Investor Meet Company a live presentation of the results on Monday, 15 February 2021 at 16:30 GMT.
• The online presentation will be open to all existing shareholders and potential new investors.
• Questions can be submitted before the event via your Investor Meet Company dashboard or at any time during the live presentation via the “Ask a Question” function. Responses to the Q&A will be published at the earliest opportunity on the Investor Meet Company platform.
• Investor feedback can also be submitted directly to management immediately following the event.
About Oncimmune
Our intimate understanding of the human immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies. The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and to give people extra time.
Oncimmune Holdings is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The company has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners.
It’s ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune’s immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.
The company is headquartered at its laboratory facility in Nottingham, UK, and has a discovery research centre in Dortmund, Germany and a partner representative office in Shanghai, China.
